Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.
about
Toxicity of polymyxins: a systematic review of the evidence from old and recent studiesBronchoscopy-guided antimicrobial therapy for cystic fibrosisAntibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisBronchoscopy-guided antimicrobial therapy for cystic fibrosisBronchoscopy-guided antimicrobial therapy for cystic fibrosisAntibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisInhaled therapy in cystic fibrosis: agents, devices and regimensClinical applications of pulmonary delivery of antibioticsThe Evolution of Cystic Fibrosis CareColistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapyAnti-Pseudomonas aeruginosa IgY Antibodies Induce Specific Bacterial Aggregation and Internalization in Human Polymorphonuclear NeutrophilsCystic fibrosisLung infections associated with cystic fibrosis.Sound waves effectively assist tobramycin in elimination of Pseudomonas aeruginosa biofilms in vitro.Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosisComparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'Feasibility study to inform the design of a randomised controlled trial to eradicate Pseudomonas aeruginosa infection in individuals with cystic fibrosisComparison of the sensitivity of culture, PCR and quantitative real-time PCR for the detection of Pseudomonas aeruginosa in sputum of cystic fibrosis patients.A laminar flow model of aerosol survival of epidemic and non-epidemic strains of Pseudomonas aeruginosa isolated from people with cystic fibrosis.Studying bacteria in respiratory specimens by using conventional and molecular microbiological approachesUncovering symptom progression history from disease registry data with application to young cystic fibrosis patients.Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders.Comparison of culture and qPCR for the detection of Pseudomonas aeruginosa in not chronically infected cystic fibrosis patients.Antipathogenic potential of marine Bacillus sp. SS4 on N-acyl-homoserine-lactone-mediated virulence factors production in Pseudomonas aeruginosa (PAO1).Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR.Early immune response to the components of the type III system of Pseudomonas aeruginosa in children with cystic fibrosisBreath sulfides and pulmonary function in cystic fibrosisAtaluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.Panax ginseng has anti-infective activity against opportunistic pathogen Pseudomonas aeruginosa by inhibiting quorum sensing, a bacterial communication process critical for establishing infectionEpidemic spread of Pandoraea apista, a new pathogen causing severe lung disease in cystic fibrosis patients.Pseudomonal infection in cystic fibrosis: the battle continues.State of progress in treating cystic fibrosis respiratory disease.Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposuresClinical significance of microbial infection and adaptation in cystic fibrosis.The rationale for aerosolized antibiotics.Pseudomonas infection in antibody deficient patients.Exhaled breath analysis using electronic nose in cystic fibrosis and primary ciliary dyskinesia patients with chronic pulmonary infections.Tracking colistin-treated patients to monitor the incidence and outcome of carbapenem-resistant Gram-negative infections.Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis
P2860
Q21092897-1EC98F85-BF95-4D07-A0FF-824FBF4C32F9Q24186413-1EAD2791-C443-4376-A932-1E590F7DBCBCQ24188054-4CAFCF72-3174-4C61-B298-2FF0BC17716AQ24201620-C194C8AB-14B8-4753-996D-B057D633432AQ24234964-36E904E1-147B-4CB3-8D1F-0CE16CFCD020Q24240388-1F419932-CA4F-478C-8201-B08A15FE1710Q26797450-E973351C-32C0-43E5-92B8-321999916583Q26996053-D3487D0F-F43E-47AA-9C15-3F85832A7C0BQ26999299-550B9FA6-10C0-42B8-9CFB-B42FA229FA3EQ27014993-2F2EC271-F389-431F-AA10-8423C5774DA6Q27322540-812EB755-64C5-4C01-92F3-96F841B936B8Q28350599-82D2FAE8-5D9E-4507-B36A-216612D44EA7Q30080000-DF8A234C-1D54-4113-A104-0F15F1075BEBQ30404353-7F9479D5-BCF7-42F5-ACAA-209409069232Q30412485-62EF98CC-2903-4DA0-9895-091E17C60F46Q30413773-13BC134D-2F93-4873-8679-70699E69E0AEQ30436229-667432AB-8572-4FD2-BB14-D21B66A5BDFDQ30493490-30578A75-3A50-4789-950F-F80F86CDF0ECQ30924268-D3EA779C-B4AB-4A34-BD1A-8582454E5321Q33346997-E91D39F4-9E2B-4887-8256-8E1D5D6C7AF7Q33430526-75A51A1F-B4C8-4DC5-A3A1-96C76DC759B9Q33467002-E466B30F-4D77-4371-8837-6ADDA2A4A51EQ33608581-2651D356-FC02-4970-B6E0-92C9D26DB170Q33702702-BF674DC5-73D5-48D8-AEDB-F8D087204288Q33858007-8096B3EC-506F-4976-882D-469806E28DB8Q34016539-0F30DADF-4EA4-4D94-9E29-A9CC7D139939Q34041909-E11B3FB9-3B46-43F5-8095-E1FCC690A92BQ34116010-27E13A63-DB85-464D-8EB2-BE0C9094706AQ34132007-A248B360-7B32-4BD2-8053-88807249726BQ34209202-4825E873-438B-4F9A-8AEC-08A19610F816Q34266590-2868181C-C0CA-4A38-910F-2E550D392D1BQ34358536-9D07B6E7-E5C3-465D-8D01-2CADFB4275B5Q34375926-453B5178-9E35-4040-B8EC-52007D0DCBBBQ34388328-F44D1930-0B38-4F81-AE17-80313F59E53FQ34491552-244AACF3-F66D-4B80-9962-CC69199C69C4Q34566912-F34B9EB0-F07A-443B-9A2F-7790CF7657E9Q34743061-BEE81ADD-9FDF-4456-AA62-4387B842F12FQ34776102-57A18C51-AD3A-44A6-A826-4C3776EABEC6Q34974577-ACB6633F-FB8C-46B2-AEA7-29F433C17D26Q35026630-FEA87DFE-8817-4B57-8EC8-EF865588B4B2
P2860
Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Antibiotic treatment of initia ...... y function in cystic fibrosis.
@en
Antibiotic treatment of initia ...... y function in cystic fibrosis.
@nl
type
label
Antibiotic treatment of initia ...... y function in cystic fibrosis.
@en
Antibiotic treatment of initia ...... y function in cystic fibrosis.
@nl
prefLabel
Antibiotic treatment of initia ...... y function in cystic fibrosis.
@en
Antibiotic treatment of initia ...... y function in cystic fibrosis.
@nl
P2093
P2860
P1476
Antibiotic treatment of initia ...... y function in cystic fibrosis.
@en
P2093
P2860
P304
P356
10.1002/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O
P577
1997-05-01T00:00:00Z